Its entry follows the launch of Wegovy, another semaglutide-based drug, in June 2025, intensifying competition in the GLP-1 receptor agonist segment
Personalized Treatment Plan Based on the assessment and diagnostic results, we create a personalized treatment plan tailored to your unique needs
In direct consideration of approving the sale of any product to the purchaser, the purchaser agrees to indemnify and hold us harmless from all claims, expenses, losses and liability of any kind arising out of the purchasers handling, possession, and/or use of the product whether used alone or in combination with any other substance
& Dayer, M
Critical evaluation Strengths - Addresses unmet need for disease modifying diabetes therapies, also applicable to related metabolic diseases - Combines regenerative potential with metabolic control - Supported by robust preclinical models and biomarker endpoints Limitations - Translational challenges in moving from preclinical models to human cells regeneration - Long term safety must be carefully evaluated, given its role in gastric physiology - Regulatory guidelines for such therapies are still evolving